DexCom, Inc. (NASDAQ:DXCM) Shares Bought by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 42.3% during the 3rd quarter, Holdings Channel reports. The firm owned 5,590 shares of the medical device company’s stock after acquiring an additional 1,662 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in DexCom were worth $370,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the stock. Jennison Associates LLC increased its holdings in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the period. Westfield Capital Management Co. LP boosted its position in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Two Sigma Advisers LP increased its holdings in DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after buying an additional 739,000 shares during the period. Canada Pension Plan Investment Board raised its position in DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after buying an additional 435,401 shares during the last quarter. Finally, Intech Investment Management LLC lifted its stake in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after acquiring an additional 369,587 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DXCM has been the topic of a number of research reports. Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Royal Bank of Canada cut their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Citigroup boosted their price objective on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Raymond James dropped their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Stock Up 5.6 %

Shares of NASDAQ DXCM opened at $80.04 on Friday. The firm has a market cap of $31.26 billion, a price-to-earnings ratio of 47.93, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The company’s 50-day simple moving average is $74.53 and its 200-day simple moving average is $83.10. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.